Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GMI-1271
Uproleselan · 1 trial · 1 indication
To assess the pharmacokinetic profile in patients with relapsed/refractory AML.
To assess the pharmacokinetic profile in patients with relapsed/refractory AML.
To assess the pharmacokinetic profile in patients with relapsed/refractory AML.
To assess the pharmacokinetic profile in patients with relapsed/refractory AML.
Number of participants with an AE.
Number of participants could tolerate the Uproleselan combined with chemotherapy.
| Arm | Type | Description |
|---|---|---|
| A Phase I, open-labeled multicenter study | EXPERIMENTAL | Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) |
| Name | Type | Description |
|---|---|---|
| Uproleselan | DRUG | A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin |
Inclusion Criteria: 1. ≥18 years and ≤60 years in age 2. AML (including secondary AML) diagnosed as per WHO standards (2008). 3. For refractory AML, only cytarabine/daunorubicin(or Idarubicin) as can be applied repeatedly(maximal twice) as induction, no other chemotherapy are allowed to be applied ...
Uproleselan is being developed for the treatment of relapsed or refractory acute myeloid leukemia (AML). It is an investigational small molecule studied in combination with chemotherapy in adult patients with relapsed or refractory AML. It is not yet approved for any indication.
Uproleselan targets SELE, also known as E-selectin, and acts as an antagonist. By blocking E-selectin, uproleselan is designed to interfere with interactions between leukemia cells and the bone marrow microenvironment. This mechanism is intended to make AML cells more responsive to chemotherapy.
Uproleselan is being developed by Apollomics Inc., which trades under the ticker APLM. The company is advancing the asset in oncology, specifically for relapsed or refractory AML.
Uproleselan is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. The completed Phase 1 trial evaluated the drug in Chinese patients with relapsed or refractory AML.
Uproleselan has been studied in one completed clinical trial, NCT04839341, titled a study to evaluate pharmacokinetics and safety with uproleselan combined with chemotherapy to treat Chinese relapsed or refractory AML patients. The Phase 1 trial enrolled 12 adults in China and was uncontrolled, non-randomized, and not double-blinded.